News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vectura Group plc (VEC.L) Presentations at ERS


9/4/2013 9:12:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Chippenham, UK – 4 September 2013: Vectura Group plc (LSE: VEC) (“Vectura”), advises that the following presentations will be made at the European Respiratory Society (ERS) Annual Congress 2013, being held in Barcelona, Spain, 7-11 September 2013.

Data to be presented at ERS by Novartis will include the latest analyses from the Phase III IGNITE clinical trial program on Ultibro® Breezhaler® (QVA149 - indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule)1,2,3. QVA149 is a once-daily investigational fixed dose combination of a long-acting beta2-adrenergic agonist (LABA) and a long-acting muscarinic antagonist (LAMA), that received a positive opinion for approval from the European Medicine Agency’s (EMA) Committee for the Human use of Medicinal Products (CHMP) in July 2013 as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.

New exacerbation, lung function and safety data will also be presented on Seebri® Breezhaler® (glycopyrronium 44 mcg delivered dose equivalent to 50 mcg metered dose per capsule)4,5 and efficacy data on Onbrez® Breezhaler® (indacaterol maleate 150 mcg)6, which are the monotherapy components of QVA149.

Alongside abstract presentations, Novartis will also be holding the following two symposia relating to COPD at ERS:

- Rethinking the treatment landscape of COPD: September 8 (17:15-19:15 CET, Room 3.13)

- Dual bronchodilation: A new treatment option for COPD patients: September 9 (17:15-19:15 CET, Room 3.13)

Vectura will be hosting a dinner on Monday 9 September for analysts and investors with a number of key opinion leaders.

For further details please contact fleur.wood@vectura.com.

ERS is the largest respiratory meeting in the world, with delegates attending from more than 100 countries. All abstracts and details on timings can be accessed through the ERS website: http://www.erscongress2013.org.

Enquiries

Vectura Group plc +44 (0)1249 667700

Chris Blackwell, Chief Executive

Karl Keegan, Corporate Development Director

FTI Consulting +44 (0)20 7831 3113

John Dineen / Ben Atwell

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES